ArticleJournal of inflammation research2025
ICAM1-Mediated Endothelial Cells and Macrophage Interactions in Modulating GBM Malignant Transformation.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- LILRB3 inhibition reverses immunosuppression in glioma: a nanoparticle-based therapeutic strategy.Journal of nanobiotechnology · 2026Article
- Intercellular adhesion molecule 1 links glioblastoma biology to a scalable prognostic model integrating clinical, imaging, and molecular features.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioblastoma (GBM) recurs frequently as the most common primary malignant brain tumor. Microvascular proliferation is a hallmark of GBM. Endothelial cells contribute to the tumor microenvironment (TME) in primary GBM and promote malignancy. However, their role in recurrent GBM (rGBM) remains unclear. Methods: An analysis was made of single-cell RNA data from GSE182109. Endothelial cells were isolated. Subclusters underwent differential expression and pseudotime trajectory analysis for the identification of signature genes. TCGA data confirmed the expression patterns and prognostic significance of signature genes. Immunofluorescence was performed on matched primary-recurrent GBM samples. Signature genes were knocked down in human umbilical vein endothelial cells (HUVECs). Co-culture experiments with THP-1 and U87 cells explored crosstalk mechanisms and their potential upstream and downstream pathways. Results: Two endothelial cell clusters were identified in single-cell analysis. Cluster 1 showed an elevation in rGBM and was associated with a poorer prognosis. Pseudotime analysis identified intercellular adhesion molecule-1 (ICAM1) as a signature gene. ICAM1 was up-regulated in rGBM, which was likely due to hypoxia. The knockdown of ICAM1 in endothelial cells reduced the adhesion of bone marrow-derived macrophages (BMDMs). Meanwhile, adrenomedullin (ADM) expression was decreased by lowering CCL2. Co-culture experiments demonstrated that macrophage-secreted ADM facilitated angiogenesis and the proliferation and migration of tumor cells. Conclusion: This study suggests that hypoxia induces endothelial cells to upregulate the expression of ICAM1 during GBM recurrence and facilitates the recruitment of BMDMs. Concurrently, endothelial-derived CCL2 induces the expression of ADM in BMDMs. This macrophage-derived ADM, in turn, accelerates angiogenesis in endothelial cells while enhancing the proliferation and migration of tumor cells. These results elucidate a feedforward loop in the endothelial-BMDM-tumor cell axis, and provide mechanistic insights into the TME of rGBM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.